undamentalytics Newsletter
Sign in

Exagen Inc. cash flow statement

In fiscal 2025, Exagen Inc.'s operations generated −$13.6m of cash; it spent $641,000 on capital projects, leaving free cash flow of −$14.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−9−10−14−20−32−14−13−14−6
Depreciation and amortisation111122222
Stock-based pay013554223
Capital spending000241111
Free cash flow−10−10−15−23−36−15−14−14−8
Free cash flow after stock pay−10−11−17−27−41−19−16−16−11
Shares issued——0690—03—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: PSNL vs XGNBNR vs XGNCDXS vs XGN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Exagen Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Exagen Inc.